I-Mab Overview
Valuation check: IMAB's ROE is -19.42%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-19.42%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
I-Mab's return on equity stands at -19.42%. That is below the Healthcare sector average of 29.39%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
I-Mab sits lower the Healthcare benchmark (29.39%) with a ROE of -19.42%. That is roughly 166.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of -19.42% for I-Mab means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how I-Mab's ROE evolved across reporting periods, while the comparison chart places IMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. I-Mab's reading of -19.42% (sector avg 29.39%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
